Indexed in

External link

License and use

Citations

Altmetrics

Analysis of institutional authors

Llufriu, SaraAuthor

Share

XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)

Publicated to:Revista De Neurologia. 79 (1): 21-29 - 2024-07-01 79(1), DOI: 10.33588/rn.7901.2024170

Authors: Fernández, O; Alonso, A; Montalbán, X; Vilaseca, A; Llufriu, S; Agüera, E; Aladro, Y; Arroyo, R; Costa-Frossard, L; García-Domínguez, JM; Meca-Lallana, V; Brieva, L; Calles, C; Eichau, S; Hernández, MA; Landete, L; Llaneza, M; Meca-Lallana, JE; Moral, E; Prieto, JM; Ramió-Torrentà, L; Téllez, N; Romero-Pinel, L; Rodríguez-Antigüedad, A

Affiliations

Abstract

The XVI Post-ECTRIMS meeting took place in Seville on 20 and 21 October 2023. This meeting was attended by neurologists specialising in multiple sclerosis (MS) from Spain, who shared a summary of the most interesting innovations at the ECTRIMS congress, which had taken place in Milan the previous week. The aim of this article is to summarise new developments related to the pathogenesis, diagnosis and prognosis of MS. The contributions of innate immunity and central nervous system resident cells, including macrophages and microglia in MS pathophysiology and as therapeutic targets were discussed. Compartmentalised intrathecal inflammation was recognised as central to understanding the progression of MS, and the relationship between inflammatory infiltrates and disease progression was highlighted. Perspectives in demyelinating pathologies were reviewed, focusing on neuromyelitis optica and myelin oligodendrocyte glycoprotein antibody-associated disease, highlighting their pathophysiological and diagnostic differences compared to MS. Advances in neuroimaging were also discussed, and especially the analysis of active chronic lesions, such as paramagnetic rim lesions. In the absence of clinical improvements in trials of remyelinating treatments, methodological strategies to optimise the design of future studies were proposed. Breakthroughs in detecting the prodromal phase of MS, the use of biomarkers in body fluids to assess activity, progression and treatment response, and research on progression independent of flares were addressed. The need to define criteria for radiologically isolated syndrome and to clarify the concept was also discussed.

Keywords